Tag: Science and Technology

A Single Dose of Cannabidiol (CBD) Reduces Blood Pressure, Study Finds

Oral CBD administration is associated with reduced blood pressure in healthy volunteers, according to clinical trial data published online in the Journal of Clinical Investigation.

Investigators from the University of Nottingham in the United Kingdom assessed the effects of a single oral dose of 600 mg of CBD extract versus placebo in nine male subjects.

Cannabidiol administration reduced resting systolic blood pressure and stroke volume (the amount of blood pumped by the left ventricle of the heart in one contraction).

Compared to placebo, CBD intake was associated with reduced BP levels following exercise and in response to stress.

Increased heart rate was observed following CBD administration, but no “adverse events” were reported by participants either during or following the study sessions.

Authors concluded:

“Our data show that a single dose of CBD reduces resting blood pressure and the blood pressure response to stress, particularly cold stress, and especially in the post-test periods. This may reflect the anxiolytic and analgesic effects of CBD, as well as any potential direct cardiovascular effects. … Further research is also required to establish whether CBD has any role in the treatment of cardiovascular disorders such as a hypertension.”

Full text of the study, “A single dose of cannabisiol reduces blood pressure in healthy volunteers in a randomized crossover study,” is online here.

Tags: , , , , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Study: Cannabis Extracts Associated With Reduced ADHD Symptoms

LONDON — The administration of whole-plant cannabis extracts is associated with improvements in cognition and behavior in subjects with Attention Deficit Hyperactivity Disorder (ADHD), according to clinical trial data published online ahead of print in the journal European Neuropsychopharmacology.

British scientists conducted a randomized, placebo-controlled trial evaluating the efficacy of cannabis extracts in 30 adults with ADHD.

Treatment was associated “with a nominally significant improvement in hyperactivity/impulsivity and a trend for improvement in inattention. There were further indications for improvement in activity and cognitive performance, and emotional lability.”

Investigators concluded:

“ADHD may represent a subgroup of individuals that gain cognitive enhancement and reduction of ADHD symptoms from the use of cannabinoids. These findings provide preliminary evidence using an experimental design for the self-medication hypothesis of cannabis use in ADHD; and support the need for further research into the effects of cannabinoids on ADHD symptoms and impairments.”

Full text of the study, “Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial,” appears in European Neuropsychopharmacology.

Tags: , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Review Identifies 140 Controlled Clinical Trials Related to Cannabis

Scientists have conducted over 140 controlled clinical trials since 1975 assessing the safety and efficacy of whole-plant cannabis or specific cannabinoids, according to a new literature review published in the journal Critical Reviews in Plant Sciences.

A team of German researchers identified 140 clinical trials involving an estimated 8,000 participants. Of these, the largest body of literature focused on the use of cannabis or cannabinoids in the treatment of chronic or neuropathic pain. Authors identified 35 controlled studies, involving 2,046 subjects, assessing the use of marijuana in pain treatment. In January, the National Academy of Sciences, Engineering, and Medicine released a comprehensive review acknowledging that “conclusive or substantial evidence” exists for cannabis’ efficacy in patients suffering from chronic pain.

Cannabinoids have also been well studied as anti-emetic agents and as appetite stimulants. Researchers identified 43 trials evaluating marijuana or its components for these purposes, involving total 2,498 patients. They also identified an additional 14 trials examining the role of cannabis or cannabis-derived extracts in the treatment of multiple sclerosis.

Researchers also identified several additional trials evaluating the use of cannabis for Crohn’s disease, Tourette’s syndrome, Parkinson’s disease, glaucoma, epilepsy, and various other indications.

A 2014 study published in the Journal of the American Medical Association reported that new drugs typically gain FDA approval on the basis of one or two pivotal clinical trials.

Full text of the study, “Medicinal uses of marijuana and cannabinoids,” appears online here.

Tags: , , , , , , , , , , , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Cannabidiol (CBD) Found to Reduce Seizure Frequency in Phase III Trial

The oral administration of CBD (cannabidiol) reduces seizure frequency in children with intractable epilepsy, according to placebo-controlled, randomized trial data published in The New England Journal of Medicine.

A team of investigators from the United States and England evaluated the effects of pharmaceutically standardized cannabidiol extracts (aka Epidiolex) versus placebo in 120 children and young adults with treatment-resistant Dravet syndrome.

They reported:

“The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with placebo.”

In April, researchers announced similar results in patients with Lennox-Gastaut syndrome, another severe form of epilepsy.

The lead author of the new study, Dr. Orrin Devinsky, director of the Comprehensive Epilepsy Center at New York University Langone Medical Center said that the findings warrant the immediate rescheduling of marijuana under federal law. “Cannabis is approved in 20 countries for spasms in multiple sclerosis,” he said. “So to say there’s no evidence of efficacy is simply untrue. … They have to de-schedule this drug. It’s just not fair to the research and clinical communities, or to the patients. It’s medieval.”

The manufacturer of Epidiolex, British biotechnology company GW Pharmaceuticals, is seeking FDA approval for its product for the treatment of severe seizure disorders.

Full text of the study, “Trial of cannabidiol for drug resistant seizures in the Dravet syndrome,” appears in The New England Journal of Medicine.

Additional information regarding the efficacy of cannabis and cannabinoids in the treatment of epilepsy is available online from NORML.

Tags: , , , , , , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Study: Marijuana Does Not Lead to an Increase in Psychotic Symptoms

PHILADELPHIA, PA — There exists “minimal evidence” in support of an association between cannabis use by itself and the onset of psychotic symptoms in young people, according to data published online ahead of print in the Journal of Adolescent Health.

Investigators from the University of Pennsylvania, Department of Psychiatry assessed the relationship between drug use and the onset of psychotic symptoms in a cohort of 4,171 young people ages 14 to 21. Authors reported that “neither frequent nor early cannabis use predicted increased odds of psychosis spectrum classification” after researchers adjusted for potential confounders (e.g., concurrent use of other substances, comorbid psychopathology, and trauma exposure).

They concluded:

“Overall, we found minimal evidence for associations between cannabis use by itself and psychosis spectrum symptoms.”

The findings are similar to those of a 2015 longitudinal study reporting that early-onset cannabis use is not positively associated with a greater risk of psychosis or other mental health disorders in mid-life.

A 2016 literature review published in the journal Current Psychiatry Reports concluded that cannabis use likely does not cause the psychosis, but rather, that subjects susceptible to the disorder may be more likely to engage in habitual use of the substance.

Full text of the study, “Cannabis use, polysubstance use, and psychosis spectrum symptoms in a community-based sample of U.S. youth,” appears in the Journal of Adolescent Health.

Tags: , , , , , , , , , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Study: Inhaled Cannabis Controls Tics in Patients With Tourette’s Syndrome

Sonya Yruel/Drug Policy Alliance

Inhaled cannabis is effective and well-tolerated in patients with Tourette’s Syndrome, according to clinical data published online ahead of print in the Journal of Neuropsychiatry and Clinical Neuroscience.

A team of researchers at the University of Toronto retrospectively assessed the safety and efficacy of inhaled cannabis in 19 TS patients.

Researchers reported, “All study participants experienced clinically significant symptom relief,” including including reductions in obsessive-compulsive symptoms, impulsivity, anxiety, irritability, and rage outbursts. Eighteen of 19 patients experienced decreased tic severity.

Cannabis was “generally well tolerated” by study subjects.

They concluded:

“Overall, these study participants experienced substantial improvements in their symptoms. This is particularly striking given that almost all participants had failed at least one anti-tic medication trial. … In conclusion, cannabis seems to be a promising treatment option for tics and associated symptoms.”

Placebo controlled data has previously determined that oral THC dosing also improves tics and obsessive-compulsive behavior in TS patients. However, patients utilizing inhaled cannabis have generally shown greater overall improvement.

An abstract of the study, “Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette Syndrome,” is online here.

Tags: , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Study: Marijuana Use Linked to Lower Prevalence of Fatty Liver Disease

Study: Marijuana Use Linked to Lower Prevalence of Fatty Liver Disease | NORML

LOWELL, MA — Subjects who consume cannabis are significantly less likely to suffer from non-alcoholic fatty liver disease (NAFLD) as compared to those who do not, according to population-based case-control data published in the journal PLOS One. Non-alcoholic fatty liver disease is the most prevalent form of liver disease in humans, affecting an estimated 80 […]

Study: Marijuana Use Linked to Lower Prevalence of Fatty Liver Disease | The Daily Chronic


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

DEA to Classify Liquid, Synthetic THC as a Schedule II Controlled Substance

WASHINGTON, DC — Officials from the US Drug Enforcement Administration (DEA) have recommended that Syndros, a liquid form of synthetic THC, be classified as a Schedule II controlled substance under federal law.

Food and Drug Administration (FDA) officials determined last year that the drug formulation is safe and effective for use by patients with cancer and AIDS.

Two other synthetic forms of THC, dronabinol and nabilone, are also FDA approved. Dronabinol (aka Marinol) is a Schedule III drug while nabilone (aka Cesamet) is Schedule II.

Syndros is the first synthetic cannabinoid in liquid form to be approved by the FDA for use by prescription.

The makers of Syndros, Insys Therapeutics, donated $500,000 last year to a political campaign to defeat Arizona’s Proposition 205, a statewide ballot initiative to regulate the adult use, cultivation, and sale of cannabis. The measure ultimately failed at the ballot box by a vote of 48 percent to 52 percent.

The company is also seeking to bring a synthetic version of cannabidiol to market.

Insys Therapeutics markets the drug SUBSYS, a spray containing the potent opioid fentanyl. Several recent studies have identified an association between state laws regulating medical cannabis access and declining rates of opioid use, abuse, hospitalizations, and mortality.

Tags: , , , , , , , , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Patients With Access to Medical Marijuana Reduce Their Use of Opioids, Study Finds

ALBUQUERQUE, NM — Patients registered to use medical cannabis decrease their use of opioids, according to data compiled by researchers at the University of New Mexico.

Investigators assessed the use of prescription opioids over an 18-month period among patients enrolled in the state’s medical marijuana program compared to similar patients who were not.

They reported that subjects with access to medical cannabis reduced their use of opioids by 31 percent while those not in the program experienced a slight increase in opioid use over this same time period.

The findings are consistent with those of other studies reporting that patients with cannabis access reduce their use of prescription medications.

Separate studies further report lower rates of opioid misuse and mortality in jurisdictions where medical marijuana is legally permitted.

Tags: ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Study: CBD-Dominant Cannabis Extracts Reduce Seizure Frequency

FALMOUTH, ME —  The administration of whole-plant cannabis extracts rich in the cannabinoid cannabidol (CBD) is associated with reduced seizure frequency in patients with refractory epilepsy, according to data published online ahead of print in the journal Epilepsy & Behavior.

Researchers performed a retrospective chart review of the clinical records of 272 patients who were taking whole-plant CBD extracts.

Eighty-six percent of those treated observed some clinical benefit (a reduction in seizure frequency) while ten percent experienced a complete clinical response. The remaining patients were either not responsive to treatment or reported an exacerbation of seizures during therapy.

Beneficial side effects, such as improved mood, better sleep quality, and increased appetite were reported.

“The cannabinoids’ novel mechanisms of action are an attractive consideration for possible seizure control,” authors concluded. “In patients with refractory epilepsy that have a low likelihood of responding to a subsequent AED (anti-epileptic drug), a trial of artisanal cannabis formulas may be indicated.”

Tags: ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.